Pcn303 - Assessing the Value of Novel Immuno-Oncology (I-O) Therapies: How Consistent Is the Health Technology Assessment (Hta) Bodies' Consideration of the Survival Benefit in the Absence of Long-Term Data?

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.385